Pulmicort Generics Win a Negative for Teva, Canaccord Says

U.S. court ruling allowing generic versions of AstraZeneca’s Pulmicort asthma treatment may spur 2% reduction in Teva EPS for 3 quarters and greater hit in 2014, Canaccord Genuity analysts led by Randall Stanicky wrote in e- mailed note. *Teva likely to lose royalty back to AstraZeneca *Teva reaffirmed hold, $45 pt **NOTE: AstraZeneca May Appeal U.S. Patent Ruling on Pulmicort Respules NSN MKMET76JTSEN <GO>

To contact the reporter on this story: Leslie Picker in New York at lpicker2@bloomberg.net

To contact the editor responsible for this story: Emma O’Brien at eobrien6@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.